Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Retained Earnings (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Retained Earnings for 4 consecutive years, with $30000.0 as the latest value for Q4 2025.

  • Quarterly Retained Earnings rose 100.0% to $30000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30000.0 through Dec 2025, up 100.0% year-over-year, with the annual reading at $30000.0 for FY2025, 100.0% up from the prior year.
  • Retained Earnings for Q4 2025 was $30000.0 at Century Therapeutics, up from -$772.7 million in the prior quarter.
  • The five-year high for Retained Earnings was $758000.0 in Q3 2024, with the low at -$782.3 million in Q4 2024.
  • Average Retained Earnings over 4 years is -$296.5 million, with a median of -$213.5 million recorded in 2022.
  • The sharpest move saw Retained Earnings tumbled 724486.11% in 2024, then surged 226.56% in 2025.
  • Over 4 years, Retained Earnings stood at -$519.1 million in 2022, then soared by 100.02% to $108000.0 in 2023, then crashed by 724486.11% to -$782.3 million in 2024, then skyrocketed by 100.0% to $30000.0 in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at $30000.0, -$772.7 million, and $83000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.